[admin]

Introduction

Evaluating reproductive and endocrine disorders requires more than a single measurement. Irregular or absent periods, infertility, recurrent miscarriage, menopausal symptoms, hirsutism, severe acne, male-pattern baldness, unexplained weight changes, galactorrhea, ovarian cysts, insulin resistance, low libido, erectile dysfunction, gynecomastia, reduced muscle mass, fatigue, depression, osteoporosis unrelated to aging, delayed or precocious puberty, and testicular abnormalities can all point toward overlapping hormonal pathways. A homogeneous CLIA hormone assay — a chemiluminescent immunoassay format that requires no separation or wash step — has become a practical format for laboratories that need consistent, quantitative endocrine results. Poclight’s Sex Hormones portfolio, built around a 9-analyte panel, illustrates how that format is applied to clinical reproductive endocrinology.

Why Multi-Analyte Hormone Assessment Matters

Endocrine dysfunction rarely announces itself through one marker. A clinician confronted with suspected polycystic ovary syndrome, ovarian failure, or androgen deficiency must separate central (hypothalamic and pituitary) causes from peripheral (gonadal and adrenal) causes. Poclight’s Sex Hormones line addresses this through a multi-tier endocrine pathway assessment that evaluates brain centers, pituitary regulators, the adrenal glands, the gonads, and placental signals.

The panel comprises nine analytes: β-hCG (Beta Human Chorionic Gonadotropin), LH (Luteinizing Hormone), FSH (Follicle-Stimulating Hormone), AMH (Anti-Müllerian Hormone), Cortisol, Testosterone, Progesterone, E2 (Estradiol), and Prolactin (PRL). Together they support clinical evaluation of reproductive development, fertility, libido, bone health, metabolic balance, menstrual regulation, and spermatogenesis.

What Each Assay Contributes

Gonadotropins and Ovarian Reserve

LH (Luteinizing Hormone) functions as a pituitary gonadotropin marker for ovarian and testicular function. It is elevated in females with polycystic ovary syndrome (PCOS), ovarian failure, and menopause, and in males with primary testicular failure and Klinefelter syndrome; it decreases in hypothalamic or pituitary dysfunction such as Kallmann syndrome. The critical diagnostic ratio is LH:FSH ≥2 in PCOS.

FSH (Follicle-Stimulating Hormone) supports evaluation of ovarian insufficiency, menopause, and testicular failure. Elevations appear in females with ovarian insufficiency (menopause or POI) and in males with primary testicular failure. Premature ovarian failure is indicated by FSH >25 IU/mL + AMH <0.5.

AMH (Anti-Müllerian Hormone) serves as an ovarian reserve and testicular developmental marker. AMH >4.7 ng/mL is diagnostic for PCOS, and AMH declines in diminished ovarian reserve and menopause. AMH is not routinely measured in males beyond infancy.

Adrenal and Steroid Signals

Cortisol reflects adrenal glucocorticoid status. Elevations accompany Cushing’s syndrome, chronic stress, and glucocorticoid therapy; decreases accompany Addison’s disease and pituitary failure with secondary adrenal insufficiency. Midnight salivary cortisol >145 ng/dL is diagnostic for Cushing’s syndrome, while AM cortisol <3 μg/dL is diagnostic for adrenal insufficiency.

Testosterone supports assessment of androgen excess or deficiency. It rises in females with PCOS, adrenal tumors, and congenital adrenal hyperplasia (CAH), and in males with testicular tumors or steroid abuse. It declines in females with hypothalamic amenorrhea and in males with hypogonadism and aging-related androgen decline.

Progesterone measures luteal function and pregnancy support. Decreased progesterone in PCOS confirms anovulation. In congenital adrenal hyperplasia, 17-OH Progesterone >10 ng/mL is diagnostic.

E2 (Estradiol) evaluates ovarian function, menopausal status, and estrogen-related conditions in both sexes. The critical ratio for premature ovarian failure is FSH:E₂ >20.

Pituitary and Placental Signals

Prolactin (PRL) is a pituitary lactotroph marker. Prolactin >250 ng/mL suggests macroprolactinoma.

β-hCG is a pregnancy and trophoblastic disease marker. Clinical interpretation requires excluding pregnancy before interpreting other hormones in females; β-hCG >100,000 mIU/mL is diagnostic for gestational trophoblastic disease.

Cross-Disease Interpretation at a Glance

The portfolio maps each analyte against eleven conditions. In PCOS, LH is strongly elevated, testosterone elevated, progesterone decreased, AMH strongly elevated, and FSH variable. In premature ovarian failure, FSH and LH rise while AMH and E2 fall. Luteal phase defect is marked by decreased progesterone. Gestational trophoblastic disease shows strongly elevated β-hCG and progesterone. Primary testicular failure presents with elevated LH and FSH and decreased testosterone, confirmed with testicular ultrasound. Klinefelter syndrome shows strongly elevated FSH and LH, decreased testosterone, elevated E2 associated with gynecomastia, and confirmatory karyotype 47,XXY. Hypogonadotropic hypogonadism is characterized by decreased LH and FSH, with pituitary lesions to be excluded. Hyperprolactinemia shows strongly elevated prolactin with suppressed LH and FSH. Cushing’s syndrome presents with cortisol elevation without diurnal rhythm. Congenital adrenal hyperplasia shows elevated testosterone with decreased cortisol. Adrenal insufficiency shows decreased cortisol.

 

Delivery Model and Clinical Fit

Poclight’s Sex Hormones assays follow a clinical laboratory testing model, with interpretation aligned to local laboratory standards or guidelines. The stated industry adaptation covers reproductive endocrinology, obstetrics and gynecology, urology, oncology, endocrinology, pediatrics, metabolic health, and andrology-adjacent practice areas.

Evidence Base

The clinical framing of the portfolio is anchored in published guidance, including Bhasin, S., et al. (2018), Testosterone therapy in men with hypogonadism, Journal of Clinical Endocrinology & Metabolism, 103(5), 1715–1744; the Endocrine Society (2011), Diagnosis and treatment of hyperprolactinemia, Journal of Clinical Endocrinology & Metabolism, 96(2), 273–288; Husebye, E. S., Pearce, S. H., Krone, N. P., & Kämpe, O. (2021), Adrenal insufficiency, Lancet, 397(10274), 613–629; the Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004), Revised 2003 consensus on diagnostic criteria, Fertility and Sterility, 81(1), 19–25; and Øksnes, M., & Husebye, E. S. (2023), Approach to the Patient: Diagnosis of Primary Adrenal Insufficiency in Adults, The Journal of Clinical Endocrinology & Metabolism, 109(1), 269–278.

Conclusion

For laboratories and clinicians seeking a structured, threshold-driven approach to reproductive and adrenal endocrinology, Poclight’s Sex Hormones portfolio — spanning β-hCG, LH, FSH, AMH, Cortisol, Testosterone, Progesterone, E2, and Prolactin — provides the analyte coverage and ratio-based interpretation framework needed to separate central from peripheral dysfunction and to move efficiently from suspicion to diagnostic clarity.

http://www.poclight.com
Nanjing Poclight Biotechnology Co., Ltd

[Author]

Posts